Vivos Therapeutics Inc (VVOS) Stock Price, Quote & News

Company Profile

Vivos Therapeutics, Inc. operates as a medical technology company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children....

Industry: Medical Devices

Sector: Healthcare

Phone: 844 672 4357

Website: www.vivos.com

Address:

7921 Southpark Plaza, Suite 210, Littleton, United States

Are_You_Experienced Sep. 10 at 2:40 AM

$VVOS I blocked KLM77. He said he sold all then comes back as who he is ..a bear.

0 · Reply

KLM_77 Sep. 9 at 9:12 PM

$VVOS $VVOS looks dangerous now ☠️!! What’s going on ? i wasn’t expecting that. People will attack me go and see by yourself. Not playing with emotions

1 · Reply

Hody35 Sep. 9 at 7:01 PM

$VVOS Seems like a good spot to start getting back in. Buying here

0 · Reply

KLM_77 Sep. 9 at 3:49 PM

$VVOS under 4 going to 3.1 just saying 🙌

3 · Reply

KLM_77 Sep. 9 at 3:13 PM

$VVOS continue the soft collapse..

0 · Reply

JD101 Sep. 9 at 2:14 PM

$LIXT $GNLX $VVOS $PBM $TNYA all in on these 5 bios … each one massive potential

0 · Reply

skips200k Sep. 9 at 1:52 PM

$VVOS Can't believe some of these stocks flying today with dilutive offerings. Wow. That's the new game, I guess. Very

0 · Reply

Muskvoice Sep. 9 at 1:37 PM

$VVOS They return 200K

0 · Reply

Muskvoice Sep. 9 at 1:32 PM

$VVOS

0 · Reply

Giovannirs3 Sep. 9 at 12:04 PM

$VVOS 👇

0 · Reply

Vivos Therapeutics, Inc. (VVOS) Q2 2025 Earnings Call Transcript

Aug 19, 2025, 4:20 PM EDT - 21 days ago

Vivos Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update

Aug 19, 2025, 8:30 AM EDT - 21 days ago

Vivos Therapeutics Schedules Release of Second Quarter 2025 Financial Results and Conference Call

Jun 26, 2025, 8:30 AM EDT - 2 months ago

New Clinical Trial Data Published Showing Positive Results from Use of Vivos Technology to Treat Obstructive Sleep Apnea in Children

May 15, 2025, 7:31 PM EDT - 4 months ago

Vivos Therapeutics, Inc. (VVOS) Q1 2025 Earnings Call Transcript

May 14, 2025, 9:15 AM EDT - 4 months ago

Vivos Therapeutics Schedules Release of First Quarter 2025 Financial Results and Conference Call

Apr 16, 2025, 8:30 AM EDT - 5 months ago

Vivos Therapeutics Signs Definitive Agreement to Acquire Largest Sleep Center Operator in Nevada

Apr 1, 2025, 12:18 AM EDT - 5 months ago

Vivos Therapeutics, Inc. (VVOS) Q4 2024 Earnings Call Transcript

Mar 31, 2025, 4:20 PM EDT - 5 months ago

Vivos Therapeutics Reports Full Year 2024 Financial Results and Provides Operational Update

Mar 28, 2025, 8:30 AM EDT - 5 months ago

Vivos Therapeutics Schedules Release of Full Year 2024 Financial Results and Conference Call

Dec 23, 2024, 8:00 AM EST - 9 months ago

Vivos Therapeutics Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Nov 14, 2024, 11:31 PM EST - 10 months ago

Vivos Therapeutics, Inc. (VVOS) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 5:00 PM EST - 10 months ago

Vivos Therapeutics Schedules Release of Third Quarter 2024 Financial Results and Conference Call

Oct 8, 2024, 7:30 AM EDT - 1 year ago

Vivos Therapeutics Granted CPT® Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices From American Medical Association

Sep 18, 2024, 7:00 AM EDT - 1 year ago

Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring

Aug 15, 2024, 2:05 PM EDT - 1 year ago

Vivos Therapeutics, Inc. (VVOS) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 4:05 PM EDT - 1 year ago

Vivos Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update

Aug 14, 2024, 7:30 AM EDT - 1 year ago

Vivos Therapeutics Schedules Release of Second Quarter 2024 Financial Results and Conference Call

Jun 27, 2024, 7:30 AM EDT - 1 year ago

Vivos Therapeutics Announces Positive Results From 7-Month Multi-Site Pilot of its New Provider-Based Marketing and Distribution Model

Jun 12, 2024, 7:30 AM EDT - 1 year ago

Vivos Therapeutics Closes $7.5 Million At-The-Market Private Equity-Backed Investment and Launches Strategic Marketing and Distribution Alliance

May 17, 2024, 9:02 PM EDT - 1 year ago

Vivos Therapeutics, Inc. (VVOS) Q1 2024 Earnings Call Transcript

May 14, 2024, 4:05 PM EDT - 1 year ago

Vivos Therapeutics Reports First Quarter 2024 Financial Results and Provides Operational Update

May 14, 2024, 7:30 AM EDT - 1 year ago

Vivos Therapeutics Schedules Release of First Quarter 2024 Financial Results and Conference Call

Apr 9, 2024, 7:30 AM EDT - 1 year ago

Vivos Therapeutics' Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursement

Mar 28, 2024, 11:10 PM EDT - 1 year ago

Vivos Therapeutics, Inc. (VVOS) Q4 2023 Earnings Call Transcript

Mar 28, 2024, 4:05 PM EDT - 1 year ago

Vivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational Update

Mar 28, 2024, 7:30 AM EDT - 1 year ago

Vivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Conference Call

Feb 6, 2024, 7:30 AM EST - 1 year ago

Vivos Therapeutics Highlights Significant Favorable Market Developments Creating Exciting New Growth Opportunities

Jan 8, 2024, 7:30 AM EST - 1 year ago

Vivos Therapeutics Sees Positive Preliminary Metrics Following Unprecedented FDA 510(k) Clearance of the Company's Proprietary Oral Medical Devices to Treat Severe OSA

Dec 11, 2023, 7:30 AM EST - 1 year ago

Vivos Therapeutics Presents Groundbreaking Event: “Empowering Women to Champion Airway”

Nov 29, 2023, 11:09 AM EST - 1 year ago

Vivos Therapeutics' stock soars as sleep apnea device gets regulatory clearance

Nov 29, 2023, 7:44 AM EST - 1 year ago

US FDA clears Vivos Therapeutics' oral device treatment for sleep apnea

Nov 29, 2023, 7:30 AM EST - 1 year ago

Vivos Therapeutics Receives First Ever FDA 510(k) Clearance for Oral Device Treatment of Severe Obstructive Sleep Apnea

Nov 17, 2023, 7:12 PM EST - 1 year ago

Vivos Therapeutics, Inc. (VVOS) Q3 2023 Earnings Call Transcript

Nov 14, 2023, 4:05 PM EST - 1 year ago

Vivos Therapeutics Reports Third Quarter 2023 Financial Results and Provides Operational Update

Nov 9, 2023, 4:30 PM EST - 1 year ago

Vivos Therapeutics Schedules Release of Third Quarter 2023 Financial Results and Conference Call

Nov 2, 2023, 5:00 PM EDT - 2 years ago

Vivos Therapeutics Closes $4 Million Private Placement

Oct 26, 2023, 7:30 AM EDT - 2 years ago

Vivos Therapeutics Announces Reverse Stock Split

Oct 24, 2023, 7:30 AM EDT - 2 years ago

Vivos Therapeutics Signs Nationwide Distribution Agreement with Lincare

Oct 11, 2023, 7:30 AM EDT - 2 years ago

Vivos Therapeutics to Begin Clinical Trial at Stanford Medicine

Oct 5, 2023, 7:30 AM EDT - 2 years ago

Vivos Therapeutics Announces Strategic Collaboration in the Middle East-North Africa Region to Support International Expansion

Oct 4, 2023, 7:30 AM EDT - 2 years ago

Vivos Therapeutics Executes Strategic Agreements with Ormco and On Demand Orthodontist To Provide Spark™ Clear Aligners to Its National Network of Providers

Oct 2, 2023, 7:30 AM EDT - 2 years ago

New York Times Best-Selling Author James Nestor to Headline List of Speakers for Fifth Annual Vivos Breathing Wellness Conference

Aug 16, 2023, 4:05 PM EDT - 2 years ago

Vivos Therapeutics Reports Second Quarter 2023 Financial Results and Provides Operational Update

Aug 16, 2023, 7:30 AM EDT - 2 years ago

Vivos Therapeutics Reschedules Second Quarter 2023 Financial Results Conference Call

Aug 14, 2023, 5:06 PM EDT - 2 years ago

Vivos Therapeutics to Reschedule Second Quarter 2023 Financial Results Conference Call

Aug 10, 2023, 8:31 PM EDT - 2 years ago

Vivos Therapeutics Schedules Release of Second Quarter 2023 Financial Results and Conference Call

Jun 9, 2023, 12:24 PM EDT - 2 years ago

Vivos Therapeutics, Inc. (VVOS) Q1 2023 Earnings Call Transcript

Jun 8, 2023, 4:05 PM EDT - 2 years ago

Vivos Therapeutics Reports First Quarter 2023 Financial Results and Provides Operational Update

Jun 6, 2023, 4:30 PM EDT - 2 years ago

Vivos Therapeutics Schedules Release of First Quarter 2023 Financial Results and Conference Call

Are_You_Experienced Sep. 10 at 2:40 AM

$VVOS I blocked KLM77. He said he sold all then comes back as who he is ..a bear.

0 · Reply

KLM_77 Sep. 9 at 9:12 PM

$VVOS $VVOS looks dangerous now ☠️!! What’s going on ? i wasn’t expecting that. People will attack me go and see by yourself. Not playing with emotions

1 · Reply

Hody35 Sep. 9 at 7:01 PM

$VVOS Seems like a good spot to start getting back in. Buying here

0 · Reply

KLM_77 Sep. 9 at 3:49 PM

$VVOS under 4 going to 3.1 just saying 🙌

3 · Reply

KLM_77 Sep. 9 at 3:13 PM

$VVOS continue the soft collapse..

0 · Reply

JD101 Sep. 9 at 2:14 PM

$LIXT $GNLX $VVOS $PBM $TNYA all in on these 5 bios … each one massive potential

0 · Reply

skips200k Sep. 9 at 1:52 PM

$VVOS Can't believe some of these stocks flying today with dilutive offerings. Wow. That's the new game, I guess. Very

0 · Reply

Muskvoice Sep. 9 at 1:37 PM

$VVOS They return 200K

0 · Reply

Muskvoice Sep. 9 at 1:32 PM

$VVOS

0 · Reply

Giovannirs3 Sep. 9 at 12:04 PM

$VVOS 👇

0 · Reply

Giovannirs3 Sep. 9 at 12:04 PM

$VVOS 👍👇

0 · Reply

Are_You_Experienced Sep. 9 at 12:00 PM

$VVOS With this pr failure to generate interest indicated in the current stock price, maybe a professional medical marketing firm should be considered once the company is on a firm footing to handle the growth. https://www.prnewswire.com/news-releases/sleep-apnea-economic-burden-in-us-exceeds-150b-annuallyvivos-novel-solution-can-help-302543780.html

0 · Reply

Are_You_Experienced Sep. 9 at 11:46 AM

$VVOS

0 · Reply

skips200k Sep. 9 at 11:45 AM

$VVOS Target price increased, and Gio is back at it. Perfect! $5.25 is closer than you think. Then lift off. Very

0 · Reply

JarvisFlow Sep. 9 at 11:30 AM

Ascendiant Capital updates rating for Vivos Therapeutics ( $VVOS ) to Buy, target set at 6.2 → 6.5.

0 · Reply

IMGroot Sep. 9 at 12:23 AM

$VVOS has anybody been tracking their open jobs? The VVOS careers website has zero available positions…

1 · Reply

HopehelpsU Sep. 8 at 11:41 PM

$VVOS The ATM, if fully used, gets VVOS into Q1 of 2026. The company claims to reach break-even by Q4, 2025. People are selling due to the S-3/A, thinking that near-term dilution is imminent. These filings are common practice, but they don't signal immediate dilution. I suspect VVOS could dilute at a fairly higher price per share. Possibly after the next ER...imo, since it appears patient counts are ramping up substantially. Here's what I put together....

1 · Reply

Giovannirs3 Sep. 8 at 9:52 PM

$VVOS 👇

0 · Reply

Giovannirs3 Sep. 8 at 9:51 PM

$VVOS 👍🤣

0 · Reply

HopehelpsU Sep. 8 at 9:43 PM

$VVOS Just a reminder....

0 · Reply

Muskvoice Sep. 8 at 8:39 PM

$VVOS 8 Out of 10 Newly Diagnosed OSA Patients Choose Oral Appliance Therapy Over CPAP and Preferred Vivos’ Flagship CARE Oral Medical Devices 5 to 1 Over Traditional Oral Appliances

0 · Reply

Muskvoice Sep. 8 at 8:21 PM

$VVOS

0 · Reply

Market Cap	28.74M
Revenue (ttm)	15.03M
Net Income (ttm)	-11.14M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-74.12%
Debt to Equity Ratio	1.73

Volume	61,600
Avg Vol	870,434
Day's Range	N/A - N/A
Shares Out	7.51M
Stochastic %K	6%
Beta	7.02
Analysts	Sell
Price Target	$5.10